首页工具

搜索结果

Search Results for " akt1-e17k "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T3467	Miransertib ARQ-092,AKT inhibitor 2	Akt; Parasite	Cytoskeletal Signaling; Microbiology/Virology; PI3K/Akt/mTOR signaling
	Miransertib (ARQ-092) 是一种具有口服活性的，选择性和变构性Akt 抑制剂。它有效抑制利什曼原虫，还是 AKT1-E17K 突变蛋白抑制剂，可研究PI3K/AKT 驱动的肿瘤和 Proteus 综合征。
T38846	Vevorisertib trihydrochloride ARQ 751 trihydrochloride	Akt	Cytoskeletal Signaling; PI3K/Akt/mTOR signaling
	Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) 是一种具有选择性和有效性的 pan-AKT 和 AKT1-E17K 突变抑制剂，抑制 AKT1 、AKT2 和 AKT3 。 Vevorisertib trihydrochloride 可用于研究肝癌和晚期实体瘤。
T22247	Miransertib (ARQ 092) HCl
	Miransertib hydrochloride (ARQ-092 hydrochloride) is a powerful, orally bioavailable, selective, and allosteric inhibitor of Akt. It exhibits an inhibitory concentration (IC50) of 2.7 nM, 14 nM, and 8.1 nM against Akt1, Akt2, and Akt3, respectively. In addition to its Akt inhibitory activity, Miransertib hydrochloride also demonstrates significant potency as an inhibitor of the AKT1-E17K mutant protein. This compound shows promise in research related to PI3K/AKT-driven tumors and Proteus syndrom...